Funding Round attributes
Invizius, a Scottish biotech company focused on developing treatments for patients undergoing dialysis, has secured £950,000 in investment funding. The round was led by Mercia Ventures, and supported by Calculus Capital, Syensqo, the University of Edinburgh’s Old College Capital and Scottish Enterprise. The funding will help Invizius advance its proprietary technology, which aims to reduce the inflammatory response in patients receiving hemodialysis, a common complication that can lead to cardiovascular disease. This investment will be used to further develop clinical trials, support regulatory approvals, and expand the company's operations as it seeks to improve outcomes for dialysis patients worldwide.
The CEO of Invizius expressed gratitude for the financial support, highlighting the importance of the funding in accelerating their mission to bring innovative solutions to market that address significant unmet medical needs. Mercia Ventures also emphasized their confidence in Invizius's technology and its potential to significantly impact patient care in the dialysis sector.
In conclusion, this investment represents a crucial step in Invizius's journey toward delivering better treatment options for dialysis patients, positioning the company for further growth and development in the medtech industry.
